Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-1: Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma and Other BCMA-Expressing Malignancies
NCT02064387Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events up to 35 months, Number of Participants With Dose-limiting Toxicities (DLTs) and 3 more. Started Jul 2014; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02064387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064387.